Securing the driving force for future growth through active R&D
Securing a globally recognized back-up pipeline

CU02 | Nonalcoholic steatohepatitis(NASH) treatment
Obesity treatment through remodeling of adipocytes
A new concept for NASH treatment using TPH1 inhibitors that do not penetrate the blood brain barrier (BBB).First, to investigate the principle of activating brown adipocyte tissue and induce beige adipocyte tissue through selective inhibition of peripheral TPH1, a synthetase of serotonin._Published in Nature Communication in 2015
Expanded indication to IBD treatment (inflammatory bowel disease) – Ulcerative colitis, Crohn’s disease
Capable of being designated an orphan drug (Carcinoid cancer, PAH)
CU04 | Immuno-oncology
Low molecular weight immuno-oncology that can be used as monotherapy
Developed a bromodomain drug (first-in-class) with an entirely new mechanism of action that is different from other immuno-oncology drugs.
Low molecular substance that creates medicinal effects in patients who are resistant to existing targeted anticancer agents
Developed compounds that enhance anticancer effect by inhibiting TREG cells through concomitant administration
Developed orally administered drug that can be provided at a lower cost
CU05 | Development of lung cancer treatment
Low molecular weight, orally administered lung cancer treatment
Developed a first-in-class AKT pathway drug with a new mechanism of action for inhibiting the combination of the AMIGO2-PDK1 PH Domain
Expected to show efficacy against advanced lung cancer
Prolongs patient survival by significantly increasing expression level in tissues of cancer patients in proximal inflammation stage when the survival rate decreases
Less toxic to normal cells compared to existing lung cancer treatment
Indication can be expanded to treatment of pancreatic cancer